What is the appropriate method to convert a chronic pain patient taking oxycodone immediate‑release 10 mg every 4 hours (total 60 mg per day) to a long‑acting oxycodone formulation, including dose reduction for cross‑tolerance and breakthrough pain dosing?

Converting Immediate-Release to Extended-Release Oxycodone in Chronic Pain

For a patient taking oxycodone IR 10 mg every 4 hours (60 mg/day total), convert to extended-release oxycodone 30 mg every 12 hours (total 60 mg/day), with immediate-release oxycodone 10-12 mg available every 4 hours as needed for breakthrough pain.

Conversion Method

Calculate Total Daily Dose

The patient is currently taking 60 mg/day of immediate-release oxycodone (10 mg × 6 doses). When converting from immediate-release to extended-release formulations of the same opioid, no dose reduction for cross-tolerance is needed since there is complete cross-tolerance 1, 2.

Determine Extended-Release Dosing

• Total daily ER dose: 60 mg/day
• Divided into: 30 mg every 12 hours 1, 3

The FDA labeling confirms that when converting from immediate-release to extended-release oxycodone, the total daily dose remains the same, divided into 12-hour intervals 2. The guideline evidence supports maintaining the same total daily opioid dose when switching between formulations of the identical opioid 1.

Breakthrough Pain Dosing

Provide 10-20% of the 24-hour total dose as immediate-release oxycodone for breakthrough pain 1:

• 10-20% of 60 mg = 6-12 mg per dose
• Practical dosing: 10 mg every 4 hours as needed
• Use the same opioid (oxycodone IR) for breakthrough doses when possible 1

Implementation Steps

1. Initiate ER oxycodone 30 mg every 12 hours on a scheduled basis
2. Prescribe oxycodone IR 10 mg every 4 hours PRN for breakthrough pain
3. Monitor closely within 24-72 hours after conversion for respiratory depression and adequate analgesia 2
4. Continue breakthrough medication during the first 1-4 weeks as the patient stabilizes 1, 4

Dose Adjustments

If the patient requires persistent use of breakthrough doses, increase the scheduled ER dose based on total opioid consumption in the previous 24 hours (scheduled + PRN doses combined) 1. Increase both the around-the-clock and as-needed doses proportionally.

Critical Safety Considerations

No dose reduction is required when converting between immediate-release and extended-release formulations of the same opioid (oxycodone to oxycodone) 2. The 25-50% dose reduction for incomplete cross-tolerance only applies when rotating between different opioids (e.g., morphine to oxycodone, or oxycodone to hydromorphone) 1.

The FDA labeling explicitly states that "the relative bioavailability of oxycodone hydrochloride tablets compared to extended-release oxycodone is unknown, so conversion to extended-release tablets must be accompanied by close observation for signs of excessive sedation and respiratory depression" 2. This emphasizes monitoring rather than empiric dose reduction.

Monitor within 1-4 weeks of starting or changing ER opioid therapy to assess benefits and harms 4. For patients at total daily doses ≥50 MME (this patient is at 90 MME), implement additional precautions including increased follow-up frequency 4, 5.

Common Pitfalls to Avoid

• Do not reduce the dose when converting from IR to ER oxycodone—this is the same drug
• Do not use ER formulations for unstable pain requiring frequent dose changes 1
• Do not prescribe ER opioids without breakthrough medication during the initial stabilization period 1
• Do not start with methadone or transdermal fentanyl as first-line ER options due to complex pharmacokinetics 5